Psilocybin is the compound most people see on labels, and psilocin is the compound your body uses for the primary psychoactive effects, so potency testing works best when it measures both and reports results in a way that ties back to dose control. Psilocybin is rapidly converted to psilocin after ingestion, and psilocin is then metabolized and cleared.
What psilocybin and psilocin are
Psilocybin and psilocin are closely related tryptamine compounds found in several mushroom species. Psilocybin includes a phosphate group. Psilocin does not. That one structural difference changes how each behaves in the body and in the lab.
When you ingest psilocybin, your body converts it to psilocin through dephosphorylation. This conversion happens quickly and is a core reason clinical pharmacology papers describe psilocybin as a prodrug for psilocin.
Psilocin then drives most of the subjective effects through serotonin receptor activity, and it is further metabolized. Human pharmacokinetic work and metabolism research describe psilocin glucuronidation as a major pathway, with psilocin-O-glucuronide commonly discussed as a primary metabolite in urine.
These basics feed directly into dose control.
- If your goal is to compare dose levels across studies, you usually compare milligrams of psilocybin administered in a controlled setting and the psilocin exposure measured in blood or urine.
- If your goal is to compare batches of biomass or extracts, you need a lab result that quantifies psilocybin and psilocin in the product itself, with methods that account for instability and conversion during handling.
Another key point is that psilocybin and psilocin do not weigh the same molecule for molecule. Public chemical databases list psilocybin at about 284.25 g/mol and psilocin at about 204.27 g/mol. That difference is the basis for common conversion factors used when programs want one combined potency number that reflects both analytes.
How labs test potency and report results
A potency test is only as useful as its sampling and method control. For psilocybin and psilocin, that means consistent grinding, mixing, extraction, filtration and analysis steps that limit degradation and limit conversion that can happen during processing. Published methods and reviews emphasize that extraction choices influence recovery and can change measured ratios between psilocybin and psilocin.
Most potency testing workflows follow the same broad sequence.
Sampling and homogenization
You start with a representative sample. If a batch is not mixed well, a small grab sample can misrepresent the batch average. This is a routine concept in analytical chemistry, but it becomes especially relevant in biomass that has uneven alkaloid distribution.
Extraction
You move analytes into a solvent. A recent extraction methods review notes that acidified methanol is commonly used, and acid conditions can help reduce psilocin degradation during extraction.
Separation and detection
You separate compounds and measure them. Liquid chromatography with tandem mass spectrometry is widely used for quantifying psilocybin and psilocin in mushroom matrices, with validated workflows describing internal standards, calibration curves and dilution strategies to deal with high concentrations and matrix effects.
Quality controls
You verify the instrument and method are behaving. This often includes blanks, spiked samples, control samples at multiple concentrations and checks for ion suppression in MS workflows.
Reports generally list results in milligrams per gram, percent by weight, or milligrams per unit for an extract or final product. Many reports list psilocybin and psilocin separately. Some also include other related tryptamines, depending on the method and program requirements. The stability and extraction literature commonly discusses multiple alkaloids, and notes that sample conditions like light and heat can shift concentrations over time.
Two practical issues affect how much you can trust a potency report.
Psilocin stability
Psilocin can oxidize and degrade more readily than psilocybin in some conditions, which is a recurring theme in stability research and in method papers that emphasize careful handling.
Conversion during preparation
Some conversions can occur during drying, storage, grinding and extraction. A well-cited stability study in Psilocybe cubensis tracked multiple alkaloids under different conditions and reported shifts over months that included changes consistent with degradation and conversion processes.
You can also see method diversity in the literature. In addition to LC-MS workflows, a 2025 paper describes a quantitative NMR approach that can quantify psilocybin and psilocin and highlights variability across samples and psilocybin to psilocin ratios.
Why some programs measure product quantity by analyte
Analyte-based measurement means you describe product strength by the amount of specific target chemicals in a serving, not only by the mass of the product itself. In this context, the analytes are typically psilocybin and psilocin.
The core reason analyte-based measurement is used is dose control across variable inputs.
If you dose by biomass weight, two equal-weight servings can contain very different amounts of psilocybin and psilocin because of cultivation conditions, genetics, part of the fruiting body, drying and storage. Stability work and quantification studies repeatedly report variability in alkaloid content across samples, and that variability is what analyte-based measurement is trying to manage.
A second reason is that psilocybin and psilocin contribute jointly to what becomes available as psilocin in the body. Psilocybin is converted to psilocin after ingestion, and psilocin already present in a product can contribute directly, even if its stability is lower.
Some regulated programs already reflect this thinking by requiring labels to list psilocybin analyte in milligrams per serving, and later adding psilocin analyte listing as a separate line item on labels starting January 1, 2026.
There is also a practical communication benefit. When a label says a serving contains a defined milligram quantity of psilocybin analyte and psilocin analyte, you can compare servings across different product forms. A capsule, a tea preparation and a chocolate can have very different weights and volumes, so analyte-based units help normalize comparison.
Programs that want a single combined number sometimes use a conversion approach that expresses psilocin as a psilocybin-equivalent amount, then adds that to measured psilocybin. That approach is based on molecular weight.
- Psilocybin molecular weight is about 284.25 g/mol. (PubChem)
- Psilocin molecular weight is about 204.27 g/mol. (PubChem)
- 284.25 divided by 204.27 is about 1.39, and 204.27 divided by 284.25 is about 0.72. (PubChem)
So if you want psilocybin-equivalent potency, one common calculation is.
Total psilocybin equivalents in mg equals measured psilocybin mg plus measured psilocin mg times 1.39
This does not change what is in the product. It changes how you express it in one number so dose control rules can be applied consistently.
You can read more about how we think about analyte-focused measurement and dose consistency in the context of lab and product science on our science page.
What this means for comparing products across batches
Batch comparison is where analyte-based labeling has the biggest practical impact. If you rely on product weight or unit count, you cannot see batch-to-batch variation. If you rely on analyte values, you can.
You get three benefits when you compare batches by psilocybin and psilocin quantities.
You see variability directly
Quantification studies and method papers report variability across samples and strains, and stability work shows levels can shift with storage. A batch label tied to analyte values lets you see those differences without needing to interpret cultivation details.
You can separate content from stability risk
A batch with higher psilocin may deliver a different profile than a batch with mostly psilocybin, but psilocin can also be more sensitive to oxidation and handling. If a report lists both, you can see that balance and you can also set storage and shelf-life plans that match risk.
You can align product dosing with research dosing logic
Clinical research often administers psilocybin in milligrams under controlled conditions, then measures psilocin exposure and clinical endpoints. Your product potency report can be expressed in milligrams of analytes, which is closer to the units used in clinical dose discussions.
There are also limits you should keep in mind when you compare batches.
Potency does not predict experience on its own
Two servings with the same analyte amounts can still feel different because of set and setting, expectations, recent sleep, food intake and other individual factors. Potency measurement is one control lever, not a full prediction system.
Method differences can distort comparisons
If one lab uses one extraction solvent and another lab uses a different approach, results can differ even on the same sample. Reviews of extraction and quantification methods stress that standardization is still a work in progress, and extraction choices can influence yields.
Stability between test date and use date can change the picture
A test report reflects the sample at the time of testing. Stability studies show changes over time under different light and temperature conditions, and those changes can affect psilocybin, psilocin and related compounds differently.
If you are trying to compare batches for dose control, you can ask for details that help you interpret the numbers.
- Date of sampling and date of analysis
- Storage conditions before sampling
- Sample preparation description, including grinding and mixing
- Method type, such as LC-MS/MS or qNMR
- Whether results are reported on a dry-weight basis or as packaged weight
- Which analytes are included in the report and which are not
You can also look for a consistent approach to expressing totals. If a program uses psilocybin-equivalent totals, it should state the conversion approach and list psilocybin and psilocin separately so you can still see the underlying profile.
If you want a deeper view into how method details connect to data reliability, you can review our research page where we focus on measurement and reproducibility themes in psilocybin science.
Quick glossary for common lab terms
Analyte
The specific chemical being measured in a lab test. In potency testing here, the analytes are commonly psilocybin and psilocin. (Labguru)
Matrix
Everything in the sample besides the analytes. In mushrooms, the matrix includes proteins, fibers, pigments and many other compounds that can affect extraction and detection. (MDPI)
Extraction
A process that moves analytes from the matrix into a solvent. Solvent choice and acidity can change recovery and stability, especially for psilocin. (PMC)
Calibration curve
A set of standards with known concentrations used to translate instrument response into a concentration value.
Internal standard
A compound added in a fixed amount to each sample to correct for loss and measurement drift. Many LC-MS methods use isotopically labeled internal standards for improved quantification. (SCIEX)
LOD and LOQ
Limits of detection and limits of quantification. These describe how low a concentration can be detected or reliably quantified by a method.
Ion suppression
A mass spectrometry effect where matrix compounds reduce signal for the analyte, leading to underestimation if not controlled. Some psilocybin and psilocin LC-MS methods note dilution and cleanup steps to reduce this issue. (MilliporeSigma)
HPLC and LC-MS/MS
Common analytical platforms. HPLC separates compounds. LC-MS/MS separates and then detects with mass spectrometry, which can improve selectivity and sensitivity. (MilliporeSigma)
Dry-weight basis
A reporting basis that removes water content effects so results are comparable across samples with different moisture.
Psilocybin equivalents
A calculated value that combines psilocybin and psilocin into one number using molecular weight conversion, often used for serving limits and cross-product comparison. (PubChem)
If you want to understand how a Massachusetts-based psychedelic research group approaches Psilocybe cubensis measurement and dose consistency, we are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
